Related Experiment Video
Updated: Aug 9, 2025
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Lipids as Targets for Renal Cell Carcinoma Therapy
Bisera Stepanovska Tanturovska1, Roxana Manaila1, Doriano Fabbro2
1Institute of Pharmacology, University of Bern, Inselspital, INO-F, CH-3010 Bern, Switzerland.
Abstract:
Kidney cancer is among the top ten most common cancers to date. Within the kidney, renal cell carcinoma (RCC) is the most common solid lesion occurring. While various risk factors are suspected, including unhealthy lifestyle, age, and ethnicity, genetic mutations seem to be a key risk factor. In particular, mutations in the von Hippel-Lindau gene (Vhl) have attracted a lot of interest since this gene regulates the hypoxia inducible transcription factors HIF-1α and HIF-2α, which in turn drive the transcription of many genes that are important for renal cancer growth and progression, including genes involved in lipid metabolism and signaling. Recent data suggest that HIF-1/2 are themselves regulated by bioactive lipids which make the connection between lipids and renal cancer obvious. This review will summarize the effects and contributions of the different classes of bioactive lipids, including sphingolipids, glycosphingolipids, eicosanoids, free fatty acids, cannabinoids, and cholesterol to renal carcinoma progression. Novel pharmacological strategies interfering with lipid signaling to treat renal cancer will be highlighted.
Insights
Kidney cancer, particularly renal cell carcinoma (RCC), is linked to genetic mutations like those in the VHL gene. Bioactive lipids significantly impact RCC progression and offer new therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Kidney cancer, especially renal cell carcinoma (RCC), is a significant health concern.
- Genetic mutations, particularly in the von Hippel-Lindau (VHL) gene, are key risk factors for RCC.
- The VHL gene regulates hypoxia-inducible transcription factors (HIFs) crucial for tumor growth.
Purpose of the Study:
- To review the role of various bioactive lipids in renal cell carcinoma progression.
- To explore the interplay between lipid signaling and HIFs in RCC.
- To highlight novel pharmacological strategies targeting lipid metabolism for RCC treatment.
Main Methods:
- Literature review of studies on kidney cancer, VHL gene, HIFs, and bioactive lipids.
- Analysis of research linking lipid metabolism to RCC pathogenesis.
- Identification of emerging therapeutic strategies targeting lipid signaling pathways.
Main Results:
- Bioactive lipids, including sphingolipids, eicosanoids, and cholesterol, significantly contribute to RCC progression.
- HIFs, regulated by VHL mutations, influence lipid metabolism genes.
- Lipid signaling pathways are implicated as drivers of renal cancer growth.
Conclusions:
- Understanding the role of bioactive lipids in RCC is crucial for developing effective treatments.
- Targeting lipid metabolism pathways presents a promising avenue for novel RCC therapies.
- The VHL-HIF-lipid axis is a key area for future research and therapeutic intervention.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...